News coverage about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. IntelliPharmaCeutics Intl earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2238006038659 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) opened at $0.81 on Friday. IntelliPharmaCeutics Intl has a fifty-two week low of $0.70 and a fifty-two week high of $3.12.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Mackie upgraded IntelliPharmaCeutics Intl to a “hold” rating and increased their price target for the stock from $1.00 to $3.10 in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $2.37.
WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/intellipharmaceutics-intl-ipci-receiving-somewhat-favorable-media-coverage-report-finds.html.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.